Background and objective.

Silicone breast implants, whether for reconstructive or aesthetic purposes, continue to be one of the most used medical devices in Plastic Surgery. Currently, there has been a boom on the possible association of this device with the appearance of autoimmune diseases, such as the ASIA Syndrome (Autoinmune Syndrome Induced by Adjuvants). However, there is no clarity about its existence or the efficacy of the clinical decisions used in its treatment.

Therefore, a review of the literature was conducted to describe the efficacy of both, pharmacological and non-pharmacological treatment alternatives for the so-called Breast Implant Associated Disease as part of ASIA Syndrome.

Methods.

A systematic review of the literature was carried out using the databases PubMed, SciELO, Scopus and Web of Science, following the PRISMA P and JBI guidelines. The search was performed using the key words: therapeutics, treatments, ASIA Syndrome, management, breast implant illness, breast implantation.

Results.

Eight articles were collected from which it is concluded that although there is symptomatic improvement after breast explantation, with or without total capsulectomy, this may be temporary and on average maintained from 1 month to 3.5 years after the procedure.

Conclusions.

Although there is symptomatic improvement with breast explantation with or without capsulectomy, there is not enough quality evidence to support this intervention, nor is there evidence on its long-term effectiveness or on non-surgical alternatives.

        · resumen en Español     · texto en Español     · Español ( pdf )